Literature DB >> 21428461

Erectile dysfunction after radical prostatectomy: treatment options.

Sidney Glina1.   

Abstract

Erectile dysfunction is a common problem after radical prostatectomy, with almost all men experiencing this complication for at least a short period after such surgery. There is evidence that early use of phosphodiesterase type 5 inhibitors, intracavernous vasoactive drugs, intraurethral alprostadil or vacuum devices can improve the recovery of postoperative erectile function. The same therapeutic modalities can be used to treat erectile dysfunction after radical prostatectomy. Physicians must be active and counsel patients and partners to improve adherence to penile rehabilitation or erectile dysfunction treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21428461     DOI: 10.2165/11588290-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  67 in total

1.  Comparative evaluation of treatments for erectile dysfunction in patients with prostate cancer after radical retropubic prostatectomy.

Authors:  J Baniel; S Israilov; E Segenreich; P M Livne
Journal:  BJU Int       Date:  2001-07       Impact factor: 5.588

2.  Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer.

Authors:  K A McCammon; P Kolm; B Main; P F Schellhammer
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

3.  Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis.

Authors:  R Raina; A Agarwal; Carlumandarlo E B Zaramo; S Ausmundson; D Mansour; C D Zippe
Journal:  Int J Impot Res       Date:  2005 Jan-Feb       Impact factor: 2.896

4.  Neuroanatomy of penile erection: its relevance to iatrogenic impotence.

Authors:  T F Lue; S J Zeineh; R A Schmidt; E A Tanagho
Journal:  J Urol       Date:  1984-02       Impact factor: 7.450

5.  Comparative effectiveness of minimally invasive vs open radical prostatectomy.

Authors:  Jim C Hu; Xiangmei Gu; Stuart R Lipsitz; Michael J Barry; Anthony V D'Amico; Aaron C Weinberg; Nancy L Keating
Journal:  JAMA       Date:  2009-10-14       Impact factor: 56.272

6.  Penile length shortening after radical prostatectomy: men's responses.

Authors:  Wellam F Yu Ko; Lesley F Degner; Thomas F Hack; Garry Schroeder
Journal:  Eur J Oncol Nurs       Date:  2009-10-06       Impact factor: 2.398

7.  Preservation of penile length after radical prostatectomy: early intervention with a vacuum erection device.

Authors:  B L Dalkin; B A Christopher
Journal:  Int J Impot Res       Date:  2007-07-26       Impact factor: 2.896

8.  Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy.

Authors:  Eric J Schwartz; Philip Wong; R James Graydon
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

9.  Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy.

Authors:  Francesco Montorsi; Gerald Brock; Jay Lee; JoAnn Shapiro; Hendrik Van Poppel; Markus Graefen; Christian Stief
Journal:  Eur Urol       Date:  2008-07-09       Impact factor: 20.096

10.  Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy.

Authors:  R A Costabile; M Spevak; I J Fishman; F E Govier; W J Hellstrom; R Shabsigh; K J Nemo; J L Rapport; P Y Tam; K L Weldon; N Gesundheit
Journal:  J Urol       Date:  1998-10       Impact factor: 7.450

View more
  2 in total

Review 1.  Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.

Authors:  Mary Lee; Roohollah Sharifi
Journal:  Drugs Aging       Date:  2018-03       Impact factor: 3.923

2.  Low-intensity pulsed ultrasound for regenerating peripheral nerves: potential for penile nerve.

Authors:  Dong-Yi Peng; Amanda B Reed-Maldonado; Gui-Ting Lin; Shu-Jie Xia; Tom F Lue
Journal:  Asian J Androl       Date:  2020 Jul-Aug       Impact factor: 3.285

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.